HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beiersdorf S&E

This article was originally published in The Rose Sheet

Executive Summary

"Extensive" investments in its North American consumer business drove organic sales in the segment up 22.3% in the first quarter, the Hamburg, Germany company announces May 6. The performance helped fuel a 4% increase in global consumer division sales to €1.32 bil. ($1.68 bil.). Strong sales in China, Russia and Brazil will continue to fuel gains in firm's consumer business, which is expected to outperform the market in 2010, Beiersdorf says. Net sales in the first quarter grew 6.9% at current exchange rates to €1.54 bil. ($1.94 bil.). The firm's after-tax profit rose 22% to €122 mil. ($156 mil.). Commenting on the performance, CEO Thomas-B. Quaas says "our development has yet to quite match our ambitious growth expectations, but we are on the right track.

You may also be interested in...



New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

BMS Has A Strong Pipeline, But Access Challenges Remain

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.

Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy

The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016907

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel